Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.

A. Cheltsov,M. Aoyagi,A. Aleshin,E. Yu,T. Gilliland,D. Zhai,A. Bobkov,John Calvin Reed,R. Liddington,R. Abagyan
DOI: https://doi.org/10.1021/jm901446n
IF: 8.039
2010-05-27
Journal of Medicinal Chemistry
Abstract:The 14 kDa homodimeric N1L protein is a potent vaccinia and variola (smallpox) virulence factor. It is not essential for viral replication, but it causes a strong attenuation of viral production in culture when deleted. The N1L protein is predicted to contain the BH3-like binding domain characteristic of Bcl-2 family proteins, and it is able to bind the BH3 peptides. Its overexpression has been reported to prevent infected cells from committing apoptosis. Therefore, interfering with the N1L apoptotic blockade may be a legitimate therapeutic strategy affecting the viral growth. By using in silico ligand docking and an array of in vitro assays, we have identified submicromolar (600 nM) N1L antagonists belonging to the family of polyphenols. Their affinity is comparable to that of the BH3 peptides (70-1000 nM). We have also identified the natural polyphenol resveratrol as a moderate N1L inhibitor. Finally, we show that our ligands efficiently inhibit growth of vaccinia virus.
What problem does this paper attempt to address?